Halozyme Therapeutics reported $97.24M in Gross Profit on Sales for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 124.93M 14.92M
Alnylam Pharmaceuticals ALNY:US $ 154.97M 35.33M
Amarin AMRN:US $ 111.83M 10.51M
Amgen AMGN:US $ 5097M 208M
Baxter International BAX:US $ 1343M 101M
Eli Lilly And LLY:US $ 5342M 555.1M
Esperion Therapeutics ESPR:US $ 8.85M 30.01M
Halozyme Therapeutics HALO:US $ 97.24M 16.2M
Intercept Pharmaceuticals ICPT:US $ 92.17M 3.79M
Intra Cellular Therapies ITCI:US $ 20.21M 2.2M
JAZZ PHA JAZZ:US $ 692.89M 60.27M
Mannkind MNKD:US $ 12.32M 1.03M
Nektar Therapeutics NKTR:US $ 19.61M 1.05M
Peregrine Pharmaceuticals PPHM:US $ 9.19M 2.2M
Pfizer PFE:US $ 14163M 2178M
Rigel Pharmaceuticals RIGL:US $ 21.39M 4.74M
United Therapeutics UTHR:US $ 417M 7.7M
Vanda Pharmaceuticals VNDA:US $ 63.3M 1.96M